Literature DB >> 23795185

Putting cardiovascular risk into perspective: A view from a pharmacist patient.

Tom Smiley1.   

Abstract

Entities:  

Year:  2013        PMID： 23795185      PMCID： PMC3676191          DOI： 10.1177/1715163513481319

Source DB:  PubMed          Journal:  Can Pharm J (Ott)        ISSN： 1715-1635


× No keyword cloud information.
  7 in total

1.  Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus).

Authors:  Ross T Tsuyuki; Kari L Olson; Alexander M Dubyk; Terri J Schindel; Jeffrey A Johnson
Journal:  Am J Med       Date:  2004-01-15       Impact factor: 4.965

Review 2.  2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.

Authors:  Jacques Genest; Ruth McPherson; Jiri Frohlich; Todd Anderson; Norm Campbell; André Carpentier; Patrick Couture; Robert Dufour; George Fodor; Gordon A Francis; Steven Grover; Milan Gupta; Robert A Hegele; David C Lau; Lawrence Leiter; Gary F Lewis; Eva Lonn; G B John Mancini; Dominic Ng; Glen J Pearson; Allan Sniderman; James A Stone; Ehud Ur
Journal:  Can J Cardiol       Date:  2009-10       Impact factor: 5.223

3.  A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP).

Authors:  Ross T Tsuyuki; Jeffrey A Johnson; Koon K Teo; Scot H Simpson; Margaret L Ackman; Rosemarie S Biggs; Andrew Cave; Wei-Ching Chang; Vladimir Dzavik; Karen B Farris; Donna Galvin; William Semchuk; Jeff G Taylor
Journal:  Arch Intern Med       Date:  2002-05-27

4.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

Review 5.  Lipids, risk factors and ischaemic heart disease.

Authors:  W P Castelli
Journal:  Atherosclerosis       Date:  1996-07       Impact factor: 5.162

Review 6.  C-reactive protein and atherogenesis: from fatty streak to clinical event.

Authors:  Radjesh J Bisoendial; John J P Kastelein; Erik S G Stroes
Journal:  Atherosclerosis       Date:  2007-07-31       Impact factor: 5.162

7.  Prevalence of conventional risk factors in patients with coronary heart disease.

Authors:  Umesh N Khot; Monica B Khot; Christopher T Bajzer; Shelly K Sapp; E Magnus Ohman; Sorin J Brener; Stephen G Ellis; A Michael Lincoff; Eric J Topol
Journal:  JAMA       Date:  2003-08-20       Impact factor: 56.272
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.